SAGA Diagnostics to Present New Pathlight™ MRD Data for Ovarian and Metastatic Breast Cancer at AACR 2026
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoring
Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform
Pathlight, a personalized, tumor-informed molecular residual disease (MRD) platform, will expand Foundation Medicine’s testing capabilities